Xcorporeal, Inc. XCRP

Company Overview

Xcorporeal, Inc. (OTC: XCRP) was a U.S.-based medical device company focused on extracorporeal blood filtration and renal support technologies. Historical public disclosures and archived market data indicate that the company developed systems intended to provide continuous blood purification therapies for patients suffering from acute kidney injury and fluid overload conditions, operating within the broader medical technology and renal care industries.

The company’s primary commercial focus centered on the development and potential commercialization of its extracorporeal therapy platform, including portable hemofiltration technologies designed for hospital and critical care environments. Available historical records suggest that Xcorporeal, Inc. pursued differentiation through compact device architecture and lower-flow blood filtration systems intended to simplify renal replacement therapy procedures. Publicly available information regarding the company’s later-stage operations, financial condition, or current commercial activity is limited, and some corporate status details are inconclusive based on available public sources.

Business Operations

Historical filings and archived investor materials indicate that Xcorporeal, Inc. primarily operated through a single medical technology business segment focused on renal assist and blood filtration systems. Revenue generation efforts historically appear to have been tied to product development, licensing discussions, clinical evaluation activities, and potential commercialization of proprietary filtration platforms rather than broad-scale recurring product sales. Data regarding sustained commercial revenue, manufacturing scale, or long-term operational profitability is inconclusive based on available public sources.

The company’s operations were concentrated in the United States, with research, development, regulatory, and corporate functions forming the core of its operating structure. Public records reference proprietary extracorporeal filtration technologies and related intellectual property assets associated with hemofiltration and ultrafiltration applications. Information concerning active subsidiaries, large-scale international joint ventures, or currently operating strategic partnerships could not be consistently verified through available public documentation.

Strategic Position & Investments

Historically, Xcorporeal, Inc. positioned itself within the emerging portable renal therapy and critical care device market, targeting healthcare providers seeking alternatives to conventional dialysis and fluid management systems. The company’s strategic direction appeared focused on advancing compact extracorporeal therapy technologies for use in intensive care and hospital settings, particularly for patients experiencing acute kidney complications. Archived public filings indicate that management emphasized clinical validation, regulatory progression, and commercialization readiness as key strategic priorities.

There is limited verifiable evidence of major acquisitions, large-scale portfolio investments, or diversified subsidiary ownership. Publicly available historical information instead suggests that the company concentrated resources on internal technology development and intellectual property advancement. Information regarding current investment activity, active institutional partnerships, or participation in newer healthcare technology sectors is inconclusive based on available public sources.

Geographic Footprint

Historical corporate disclosures indicate that Xcorporeal, Inc. was headquartered in the United States, with operations and development activities primarily concentrated domestically. Available records do not demonstrate a broad multinational operating footprint comparable to larger publicly traded medical device manufacturers.

While the company’s medical technologies were intended for potential use in global healthcare markets, especially hospital and critical care settings, publicly verifiable evidence of extensive commercial penetration across Europe, Asia-Pacific, or other international regions remains limited. Data regarding current international operations, overseas manufacturing, or foreign investment activity is inconclusive based on available public sources.

Leadership & Governance

Historical SEC and market records identify a number of executives and directors associated with Xcorporeal, Inc. during its operational period, although current leadership status and governance structure could not be conclusively verified. Management strategy historically appeared centered on advancing proprietary renal support technologies through regulatory development and commercialization pathways within the medical device sector.

Key historical executives and leadership figures associated with the company include:

• Ronald W. Maldonado – Chief Executive Officer
• Richard M. Russo – Chairman
• Barry A. Cheswick – Chief Financial Officer

Additional current executive leadership information, board composition details, and updated governance disclosures are inconclusive based on available public sources, including archived SEC filings and historical market records.